Tarsus Pharmaceuticals Stock Drops as Short Seller Alleges Illegal Copay Scheme - Tarsus Pharmaceuticals
Short seller Culper alleges Tarsus Pharmaceuticals (TARS) used a Healthwell Foundation blepharitis fund to cover Medicare copays for XDEMVY patients, potentially violating the Anti-Kickback Statute, citing $5.7M (2023), $31.2M (2024), and $78.5M (2025) in donations. Culper also disputes Tarsus’s addressable market and 2026 profit estimates. TARS shares fell 4.5% to $60.11.
How this was made
The 30-second read
Why it matters
If substantiated, the allegations could trigger regulatory scrutiny, potential enforcement, and a reassessment of XDEMVY’s addressable market and profit trajectory; even as claims, they can move the stock via risk repricing.
Market read
The newest tradable element is the specific, quantified allegation set (donation totals, patient-diagnosis survey, and profit estimate critique) coinciding with a same-day stock drop.
What to watch
The article doesn’t include any regulator action, court filing, or company rebuttal; traders may need to wait for primary documents (complaints, filings, or Tarsus statements) before extrapolating to earnings impact.
Background
Culper (a short seller) alleges Tarsus’s XDEMVY sales were supported via Medicare copay coverage routed through the Healthwell Foundation and a specialty pharmacy relationship (BlinkRx).
Ticker impact
Benzinga reports short-seller Culper alleges Tarsus used donations to cover Medicare copays for XDEMVY, potentially violating the Anti-Kickback Statute.
Near-term downside bias as traders price in heightened legal/regulatory risk and lower revenue/profit expectations.
The article cites specific donation amounts, a channel (BlinkRx), and a lower patient-diagnosis rate, plus notes the stock is down ~4.5% at publication.
Market effects
Highlights heightened scrutiny risk for specialty pharma patient-assistance/copoly programs under the Anti-Kickback Statute, which can pressure peers’ sentiment even without direct allegations.
Limited direct regional spillover; primarily US regulatory/legal risk perception for specialty pharma.
Low—mostly US Medicare compliance and US commercialization economics.
Counterpoint
Tarsus disputes are not presented; the piece is a short-seller claim, so the market may overreact until the company responds or regulators provide clarity.
Key entities
- companyTarsus Pharmaceuticals
Subject of the article; stock is down and faces allegations about Medicare copay support, addressable market assumptions, and inflated profit estimates.
- short_sellerCulper
Short seller making the allegations and stating it is short the stock.
- foundationHealthwell Foundation
Charity fund Culper alleges was used to cover Medicare copays for XDEMVY patients.
- specialty_pharmacyBlinkRx
Specialty pharmacy Culper alleges is tightly linked to routing Medicare patients to the fund.
